Last Updated: May 31, 2026

Details for New Drug Application (NDA): 012772

✉ Email this page to a colleague

NDA 012772 describes HALDRONE, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the HALDRONE profile page.

The generic ingredient in HALDRONE is paramethasone acetate. There are two drug master file entries for this compound. Additional details are available on the paramethasone acetate profile page.

Summary for 012772

Tradename:	HALDRONE
Applicant:	Lilly
Ingredient:	paramethasone acetate
Patents:	0

Medical Subject Heading (MeSH) Categories for 012772

Anti-Inflammatory Agents
Glucocorticoids

Profile for product number 005

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	1MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Profile for product number 006

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	2MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Expired US Patents for NDA 012772

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-005	Approved Prior to Jan 1, 1982	3,499,016	⤷ Start Trial
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-006	Approved Prior to Jan 1, 1982	3,499,016	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.